Fig. 2: Cumulative incidences (CIs) of graft-versus-host-disease (GVHD) between low-dose post-transplant cyclophosphamide (PTCy) combined with low-dose anti-thymocyte globulin (ATG) and standard-dose ATG cohorts. | Bone Marrow Transplantation

Fig. 2: Cumulative incidences (CIs) of graft-versus-host-disease (GVHD) between low-dose post-transplant cyclophosphamide (PTCy) combined with low-dose anti-thymocyte globulin (ATG) and standard-dose ATG cohorts.

From: Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial

Fig. 2

a The CI of grade II-IV acute GVHD (aGVHD); b The CI of grade III-IV aGVHD; c The 2-year CI of chronic GVHD (cGVHD); d The 2-year CI of moderate to severe cGVHD.

Back to article page